Lesson
Definition, Chronicity, and Cause
CKD is an abnormality of kidney structure or function present for at least three months with implications for health. The diagnosis requires evidence, duration, and a search for cause.
- Three-month chronicity
- Markers of kidney damage
- Reduced GFR
- Cause evaluation
- AKI and AKD distinction
eGFR, albumin, sediment, imaging, histology, transplant
Prior records, repeat testing, imaging, or pathology
History, urine, serology, imaging, genetics, or biopsy
Prove the diagnosis
CKD is present when an abnormality of kidney structure or function persists for at least three months and affects health. An eGFR below 60 mL/min/1.73 m2 can qualify, as can albuminuria, urine sediment abnormalities, persistent hematuria, tubular disorders, histologic or imaging abnormalities, or a history of kidney transplantation.
Establish chronicity
Use prior eGFR and urine albumin records, imaging that shows chronic structural change, pathology, or repeated measurements beyond three months. Do not assume chronic disease from one abnormal result. Repeat testing sooner when acute illness, obstruction, glomerular disease, or a rapid change is possible.
Name the cause
The CGA framework begins with cause. Review diabetes, hypertension, vascular disease, immune and systemic disorders, family history, congenital disease, stones, obstruction, infections, pregnancy history, toxins, medications, urine sediment, albumin pattern, and imaging. A common risk factor does not automatically prove etiology.
Recognize diagnostic red flags
Rapid eGFR loss, active urine sediment, nephrotic-range protein, systemic inflammation, refractory hypertension, recurrent stones, unexplained electrolyte disorders, or inherited-disease clues can justify serology, imaging, genetics, biopsy, or nephrology referral rather than routine risk-factor management alone.
Quick check
Checking for saved practice…
Lesson
Detection, Mechanism, and Presentation
CKD is often silent until filtration is substantially reduced. Detection begins with the right population, while mechanism explains why surviving nephrons can preserve function before progressive injury becomes clinically visible.
- Risk-based detection
- Hyperfiltration
- Maladaptive nephron response
- Silent progression
- Uremic presentation
Pair filtration with urine albumin in people at increased risk
Preserved total GFR can coexist with rising intraglomerular stress
Nephron loss, systemic complications, and symptoms emerge over time
Test people at increased risk
Use both a filtration estimate and urine albumin assessment in people at increased risk, including those with diabetes, hypertension, cardiovascular disease, prior AKI, structural or inherited kidney disease, obstruction, recurrent stones, systemic inflammatory disease, or relevant medication exposure. Type 2 diabetes warrants kidney assessment from diagnosis. Type 1 diabetes commonly begins annual assessment five years after diagnosis unless clinical findings justify earlier testing.
Follow the surviving nephron
After nephron loss, remaining nephrons increase single-nephron filtration to preserve total GFR. Sustained intraglomerular pressure, angiotensin signaling, protein traffic, oxidative stress, inflammation, and growth-factor activity can turn compensation into podocyte injury, tubular stress, interstitial fibrosis, and further nephron loss.
Do not wait for symptoms
People with G1 through G3 CKD are frequently asymptomatic. Edema, resistant hypertension, appetite loss, nausea, pruritus, sleep disturbance, cognitive change, neuropathic symptoms, dyspnea, and altered urine volume are more likely as disease advances, but none is a sensitive screening test. Laboratory surveillance should precede symptom-driven discovery.
Separate the syndrome from the number
Advanced CKD affects sodium and water balance, potassium and acid-base regulation, erythropoiesis, mineral metabolism, drug handling, and cardiovascular health. Uremia is a clinical syndrome caused by retained solutes and systemic consequences, not a diagnosis made from one BUN, creatinine, or eGFR threshold.
Quick check
Checking for saved practice…
Lesson
CGA Classification and Measurement
Cause, GFR category, and albuminuria category describe different dimensions of CKD. Their intersection predicts outcomes better than either laboratory value alone.
- G1 through G5
- A1 through A3
- Urine ACR
- Creatinine and cystatin C
- CGA heat map
Diabetic, vascular, glomerular, inherited, obstructive, or other
G1 through G5 describe filtration severity
A1 through A3 add independent prognostic information
Classify filtration
GFR categories are G1 at 90 or greater, G2 at 60 to 89, G3a at 45 to 59, G3b at 30 to 44, G4 at 15 to 29, and G5 below 15 mL/min/1.73 m2. G1 or G2 does not establish CKD without another marker of kidney damage.
Quantify albuminuria
Urine albumin-to-creatinine ratio is preferred for initial albumin assessment. A1 is below 30 mg/g, A2 is 30 to 300 mg/g, and A3 is above 300 mg/g. Confirm an unexpected positive result with a quantitative first-morning sample when practical and consider exercise, fever, infection, menstruation, and marked hyperglycemia.
Choose a filtration estimate
Creatinine-based eGFR is the usual initial estimate. Cystatin C can improve classification when muscle mass, diet, amputation, severe illness, or a treatment threshold makes creatinine less reliable. Combined creatinine and cystatin C equations generally improve precision when the result will change a decision.
Read the heat map as risk
The same eGFR carries different risk at different albuminuria levels. Increasing G category and A category raise the probability of kidney failure, cardiovascular events, AKI, hospitalization, and death. The heat map guides intensity but does not replace cause, trajectory, age, comorbidity, or patient priorities.
Quick check
Checking for saved practice…
Lesson
Progression, Risk, and Referral
Current status, direction of travel, and an absolute risk estimate answer different questions. Together they determine follow-up, referral, and kidney failure preparation.
- eGFR slope
- Albuminuria trend
- KFRE
- Monitoring frequency
- Nephrology referral
Defines the current kidney phenotype
Separates stable disease from sustained progression
Connects absolute kidney failure risk to action
Measure trajectory
Plot eGFR and albuminuria over time rather than comparing only two values. Confirm unexpected changes, account for intercurrent illness and treatment initiation, and investigate a sustained decline or a change that exceeds expected biologic and analytic variability.
Estimate absolute risk
For many adults with G3 to G5 CKD, the Kidney Failure Risk Equation combines age, sex, eGFR, and urine ACR to estimate two-year and five-year kidney failure risk. Use a validated regional implementation and do not substitute the number for clinical judgment in populations where it is not validated.
Match surveillance to risk
Monitor eGFR and albuminuria at least annually in CKD, with more frequent review as risk rises, after treatment changes, or when a result will change management. Blood pressure, potassium, glucose, medication exposure, and disease-specific markers belong to the same monitoring plan.
Refer for a reason
Nephrology referral is appropriate for diagnostic uncertainty, active sediment, significant albuminuria, rapid progression, refractory hypertension, persistent potassium or acid-base disorders, hereditary disease, recurrent stones, advanced CKD, or a kidney failure risk that warrants multidisciplinary planning. Urgency depends on the phenotype.
Quick check
Checking for saved practice…
Lesson
Foundations of Kidney Protection
Kidney protection is a coordinated plan for blood pressure, RAAS activity, sodium and tobacco exposure, physical activity, lipids, vaccination, cardiovascular risk, and patient goals.
- Standardized blood pressure
- ACE inhibitor or ARB
- Lifestyle care
- Cardiovascular prevention
- Layered therapy
Standardized measurement and tolerated blockade
A feasible plan that preserves nutrition
Treat the competing risk, not creatinine alone
Measure pressure correctly
Use standardized office technique and out-of-office measurements when needed before escalating therapy. KDIGO supports a systolic target below 120 mm Hg for many adults with high blood pressure and CKD when tolerated and measured in a standardized manner. Individualize for frailty, falls, symptoms, limited life expectancy, and measurement context.
Use RAAS blockade for the right phenotype
An ACE inhibitor or ARB is central for albuminuric CKD, especially with diabetes. Use the highest approved tolerated dose, check creatinine and potassium after initiation or titration, and avoid routine ACE inhibitor plus ARB combination. A modest early eGFR change may reflect the intended intraglomerular hemodynamic effect.
Build the nonpharmacologic layer
Counsel on sodium reduction, regular physical activity, tobacco cessation, healthy weight and dietary pattern, and protein intake appropriate to CKD and nutritional status. Avoid excessive protein intake in adults at risk of progression. Adapt potassium and phosphorus advice to measured problems rather than imposing unnecessary universal restriction.
Treat cardiovascular risk
CKD is a cardiovascular risk state. Use statin-based therapy according to age, CKD stage, dialysis status, transplant status, and guideline context. Address diabetes, pressure, tobacco, activity, vaccines, antiplatelet indications, sleep, and heart failure rather than focusing on creatinine alone.
Quick check
Checking for saved practice…
Lesson
Disease-Modifying Pharmacotherapy
RAAS inhibitors, SGLT2 inhibitors, and selected mineralocorticoid receptor antagonism act through complementary pathways. Benefits depend on indication, sequencing, tolerance, and monitoring.
- SGLT2 inhibition
- Expected eGFR dip
- Finerenone
- GLP-1 receptor agonists
- Combination strategy
ACE inhibitor or ARB for the indicated phenotype
Kidney and heart benefit beyond glycemia
Select by diabetes, albuminuria, potassium, and cardiovascular need
Use SGLT2 inhibitors for organ protection
SGLT2 inhibitors reduce CKD progression and cardiovascular events in defined CKD populations, including many people without diabetes. KDIGO recommends treatment for adults with CKD and eGFR at least 20 mL/min/1.73 m2 plus urine ACR at least 200 mg/g, or heart failure irrespective of albuminuria, with additional evidence-based use in other groups.
Expect a hemodynamic dip
A small reversible eGFR decrease after SGLT2 initiation usually reflects reduced intraglomerular pressure and is not by itself a reason to stop. Reassess volume, diuretics, NSAIDs, acute illness, pressure, obstruction, and the magnitude and trajectory when the change is larger or the patient is symptomatic.
Add nonsteroidal MRA therapy selectively
Finerenone can reduce kidney and cardiovascular events in adults with CKD associated with type 2 diabetes who meet eGFR, albuminuria, and potassium criteria while receiving tolerated RAAS inhibition. Check potassium and eGFR before initiation, again about four weeks later, after dose changes, and periodically. Strong CYP3A4 inhibitors are contraindicated.
Layer diabetes and cardiovascular benefit
A long-acting GLP-1 receptor agonist is valuable when type 2 diabetes remains above the individualized glycemic goal despite metformin and SGLT2 therapy, when those agents cannot be used, or when cardiovascular and weight benefits are priorities. Titrate slowly, counsel on gastrointestinal effects, and account for insulin or secretagogue hypoglycemia risk.
Quick check
Checking for saved practice…
Lesson
Treatment Monitoring and Response
A kidney-protective prescription is incomplete until expected changes, safety measurements, response thresholds, and ownership are documented.
- RAAS response
- Hyperkalemia mitigation
- SGLT2 safety
- Finerenone titration
- Response ownership
Choose timing from therapy and individual risk
Separate hemodynamic response from progressive injury
Document thresholds, timing, and clinical ownership
Monitor RAAS blockade as a pathway
Before and after starting or increasing an ACE inhibitor or ARB, assess pressure, creatinine, potassium, volume, NSAID exposure, and interacting medicines. Recheck within two to four weeks, or sooner when risk is high. Continue when changes are expected and stable. A creatinine rise above 30 percent within four weeks prompts evaluation for volume depletion, medications, obstruction, or renal artery disease before a final dose decision.
Keep creatinine and eGFR changes distinct
KDIGO advises continuing an ACE inhibitor or ARB unless creatinine rises more than 30% within four weeks after initiation or dose increase. Its response algorithm also uses an eGFR fall of at least 30% to trigger investigation. These are different measurements, not interchangeable percentage changes. Creatinine rising from 1.0 to 1.4 mg/dL is a 40% increase: (1.4 - 1.0) / 1.0 × 100. Assess reversible causes and clinical safety rather than treating either number as a complete diagnosis.
Manage potassium before surrendering benefit
When RAAS therapy causes hyperkalemia, review diet in context, constipation, supplements, salt substitutes, NSAIDs, trimethoprim, potassium-sparing drugs, acidosis, and volume status. Diuretics, bicarbonate for appropriate metabolic acidosis, and potassium binders may preserve indicated therapy. Reduce or stop treatment when hyperkalemia remains uncontrolled or symptomatic hypotension persists despite mitigation.
Pair SGLT2 benefit with practical safety
Assess volume and diuretic burden, genital infection history, diabetes medicines, ketosis risk, fasting, and procedures. Counsel on genital hygiene, symptoms of infection, volume depletion, and ketoacidosis. Withhold during prolonged fasting, surgery, or critical illness, then document restart criteria. A reversible early eGFR dip usually does not require extra CKD monitoring by itself.
Use potassium to govern finerenone
Confirm type 2 diabetes with CKD, persistent albuminuria, tolerated RAAS inhibition, eGFR eligibility, serum potassium, and absence of a strong CYP3A4 inhibitor. Select the labeled starting dose from eGFR, repeat potassium at about four weeks, and use the current label thresholds to continue, titrate, hold, or restart rather than improvising a fixed rule.
Quick check
Checking for saved practice…
Lesson
Medication Stewardship and Longitudinal Care
CKD changes drug clearance, exposure, benefit, and vulnerability. Safe care depends on the right kidney estimate, dose, monitoring interval, temporary interruption plan, and transition process.
- Renal dose assessment
- Nephrotoxin stewardship
- Sick-day planning
- Procedure safety
- Shared longitudinal care
Verify eGFR, creatinine clearance, stability, and context
Balance exposure, benefit, toxicity, and alternatives
Set timing, thresholds, hold and restart criteria
Use the estimate required by the drug
FDA labels may base dosing on eGFR, creatinine clearance, or another threshold. Verify the label and calculation method, especially near a cutoff, at extreme body size, or with unstable kidney function. Therapeutic drug monitoring and clinical response can be more informative than an equation alone for narrow-index medicines.
Prevent avoidable injury
Review NSAIDs, duplicate RAAS blockade, herbal products, bowel preparations, antimicrobials, contrast, and medications that accumulate. Nephrotoxin stewardship means identifying necessity, mechanism, alternatives, duration, dose, combinations, and surveillance, not labeling every medication as forbidden.
Plan for illness and procedures
Give individualized instructions for vomiting, diarrhea, fasting, major procedures, and severe infection. SGLT2 inhibitors require advance interruption before major surgery or prolonged fasting because ketoacidosis can occur with only modest glucose elevation. Avoid indiscriminate sick-day lists that cause prolonged loss of beneficial therapy.
Close every transition
At each visit and care transition, reconcile medicines, update kidney function and albuminuria, assess adherence and access, review vaccines and cardiovascular risk, and state who will follow abnormal results. Any temporary hold needs a reason, restart criteria, date, and owner.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 120 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.